Concepedia

Carly Campbell

CC

Statistics

Publications

9

Citations

430

H-Index

9

Active since

2014

Affiliations

Bicycle Therapeutics (United Kingdom)(Current)

Epizyme (United States)

Sarah Cannon

Tennessee Oncology

The University of Texas MD Anderson Cancer Center

Carly Campbell is an author at Bicycle Therapeutics (United Kingdom) specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

2014–2024

9

Publications

9

DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia

Rachel E. Rau, Min Luo, Mira Jeong et al. · Blood · 2016 · 123 citations · Full text

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in <i>MLL</i> -Rearranged Leukemia

Carly Campbell, Jessica N. Haladyna, David A. Drubin et al. · Molecular Cancer Therapeutics · 2017 · 62 citations

BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors

Michael Rigby, Gavin Bennett, Liuhong Chen et al. · Molecular Cancer Therapeutics · 2022 · 60 citations · Full text

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

Marjorie G. Zauderer, Peter W. Szlosarek, Sylvestre Le Moulec et al. · Journal of Clinical Oncology · 2018 · 52 citations

, , +17

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Eytan M. Stein, Guillermo Garcia‐Manero, David A. Rizzieri et al. · Blood · 2014 · 44 citations

1–5 of 9